Long-Term Data Demonstrate Sustained DFS Benefit With Adjuvant Pembrolizumab in ccRCC
ccRCC | Image by Ashling Wahner & MJH Life Sciences Using AI Adjuvant pembrolizumab (Keytruda) demonstrated prolonged disease-free survival (DFS) and overall survival (OS) compared with placebo in patients with clear cell renal cell carcinoma (ccRCC), according to a landmark 5-year analysis from the phase 3 KEYNOTE-564 trial (NCT03142334) presented at the 2025 ASCO Annual … Read more